- Advanced search
- Immuno Portal
- Malaria Portal
Ligand id: 2770
View more information in the IUPHAR Pharmacology Education Project: paclitaxel
Molecular properties generated using the CDK
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|No information available.|
|Summary of Clinical Use|
|Solvent-based paclitaxel is approved to treat lung, ovarian and breast cancers and Kaposi's sarcoma.
Nab-paclitaxel is designated as an orphan drug by the US FDA, for the treatment of metastatic adenocarcinoma of the pancreas (in combination with gemcitabine). It is fully approved for this indication and for use in certain breast cancer patients (with tumours unresponsive to other chemotherapy, or relapsed disease) and non-small-cell lung cancer (NSCLC).
|Mechanism Of Action and Pharmacodynamic Effects|
|Paclitaxel binds to the β-subunit of tubulin, which prevents the microtubule/paclitaxel complex from disassembling. This prevents normal microtubulin growth and function by stopping the microtubules from shortening and lengthening as they normally would.|
For extended ADME data see the following:
Electronic Medicines Compendium (eMC)
European Medicines Agency (EMA)